Effect and Molecular Mechanisms of Traditional Chinese Medicine on Regulating Tumor Immunosuppressive Microenvironment

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Guo, Qiujun ^a,b   Li, Jie ^a   Lin, Hongsheng ^a  

^a INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^b BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FAS LIGAND;

ANGIOGENESIS; ANTIGEN PRESENTATION; APOPTOSIS; CANCER IMMUNOTHERAPY; CANCER STEM CELL; CARCINOGENICITY; CELL PROLIFERATION; CHINESE MEDICINE; DENDRITIC CELL; EXTRACELLULAR MATRIX; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; LYMPHANGIOGENESIS; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR MECHANICS; PHENOTYPE; PROTEIN EXPRESSION; REVIEW; SUPPRESSOR CELL; T LYMPHOCYTE; TH1 TH2 BALANCE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR GROWTH; TUMOR INVASION; TUMOR MICROENVIRONMENT; WESTERN MEDICINE; CARCINOGENESIS; DISEASE COURSE; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; PATHOLOGY;

CARCINOGENESIS; DISEASE PROGRESSION; HUMANS; IMMUNOSUPPRESSION; IMMUNOTHERAPY; MEDICINE, CHINESE TRADITIONAL; TUMOR MICROENVIRONMENT;

EID: 84934301339     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/261620     Document Type: Review

References (95)

1. G. P. Dunn, A. T. Bruce, H. Ikeda, L. J. Old, and R. D. Schreiber, "Cancer immunoediting: from immunosurveillance to tumor escape", Nature Immunology, vol. 3, no. 11, pp. 991-998, 2002.
2. G. P. Dunn, L. J. Old, and R. D. Schreiber, "The three Es of cancer immunoediting", Annual Review of Immunology, vol. 22, pp. 329-360, 2004.
3. J. Li and H.-S. Lin, "Integrative medicine: a characteristic China model for cancer treatment", Chinese Journal of Integrative Medicine, vol. 17, no. 4, pp. 243-245, 2011.
4. J. Li, L. Li, R. Liu, and H.-S. Lin, "Establishing Chinese medicine characteristic tumor response evaluation system is the key to promote internationalization of Chinese medicine oncology", Chinese Journal of Integrative Medicine, vol. 18, no. 10, pp. 730-736, 2012.
5. L. Xu, J.-M. Feng, J.-X. Li et al., "Tanshinone-1 induces tumor cell killing, enhanced by inhibition of secondary activation of signaling networks", Cell Death & Disease, vol. 4, article e905, 2013.
6. Y. Jia, Q. Guan, Y. Guo, and C. Du, "Reduction of inflammatory hyperplasia in the intestine in colon cancer-prone mice by water-extract of Cistanche deserticola", Phytotherapy Research, vol. 26, no. 6, pp. 812-819, 2012.
7. M. Egeblad, E. S. Nakasone, and Z. Werb, "Tumors as organs: complex tissues that interface with the entire organism", Developmental Cell, vol. 18, no. 6, pp. 884-901, 2010.
8. G. Kochan, D. Escors, K. Breckpot, and D. Guerrero-Setas, "Role of non-classical MHC class I molecules in cancer immunosuppression", OncoImmunology, vol. 2, no. 11, article ID e26491, 2013.
9. C. Fremd, F. Schuetz, C. Sohn, P. Beckhove, and C. Domschke, "B cell-regulated immune responses in tumor models and cancer patients", OncoImmunology, vol. 2, no. 7, article ID e25443, 2013.
10. D. Lindau, P. Gielen, M. Kroesen, P. Wesseling, and G. J. Adema, "The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells", Immunology, vol. 138, no. 2, pp. 105-115, 2013.
11. S. Ostrand-Rosenberg, P. Sinha, D. W. Beury, and V. K. Clements, "Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression", Seminars in Cancer Biology, vol. 22, no. 4, pp. 275-281, 2012.
12. G. Landskron, M. de La Fuente, P. Thuwajit, C. Thuwajit, and M. A. Hermoso, "Chronic inflammation and cytokines in the tumor microenvironment", Journal of Immunology Research, vol. 2014, article ID 149185, 19 pages, 2014.
13. H. W. Chung and J.-B. Lim, "Role of the tumor microenvironment in the pathogenesis of gastric carcinoma", World Journal of Gastroenterology, vol. 20, no. 7, pp. 1667-1680, 2014.
14. H. Bolouri, "Network dynamics in the tumor microenvironment", Seminars in Cancer Biology, vol. 30, pp. 52-59, 2015.
15. J. M. Fritz, L. D. Dwyer-Nield, and A. M. Malkinson, "Stimulation of neoplastic mouse lung cell proliferation by alveolar macrophage-derived, insulin-like growth factor-1 can be blocked by inhibiting MEK and PI3K activation", Molecular Cancer, vol. 10, article 1476, 2011.
16. F. Munari, S. Lonardi, M. A. Cassatella et al., "Tumor-associated macrophages as major source of APRIL in gastric MALT lymphoma", Blood, vol. 117, no. 24, pp. 6612-6616, 2011.
17. M. Yang, J. Chen, F. Su et al., "Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells", Molecular Cancer, vol. 10, article 117, 2011.
18. S. E. J. Chambers, C. L. O'Neill, T. M. O'Doherty, R. J. Medina, and A. W. Stitt, "The role of immune-related myeloid cells in angiogenesis", Immunobiology, vol. 218, no. 11, pp. 1370-1375, 2013.
19. B. Zhang, G. Yao, Y. Zhang, J. Gao, B. Yang, and Z. Rao, "M2-Polarized tumor-associated macrophages are associated with poor prognoses resulting from accelerated lymphangiogenesis in lung adenocarcinoma", Clinics, vol. 66, no. 11, pp. 1879-1886, 2011.
20. M. de Palma and L. Naldini, "Angiopoietin-2 TIEs up macrophages in tumor angiogenesis", Clinical Cancer Research, vol. 17, no. 16, pp. 5226-5232, 2011.
21. S. Ran and K. E. Montgomery, "Macrophage-mediated lymphangiogenesis: the emerging role of macrophages as lymphatic endothelial progenitors", Cancers, vol. 4, no. 3, pp. 618-657, 2012.
22. R. Guiet, E. van Goethem, C. Cougoule et al., "The process of macrophage migration promotes matrix metalloproteinaseindependent invasion by tumor cells", The Journal of Immunology, vol. 187, no. 7, pp. 3806-3814, 2011.
23. T. Tsuji, S. Ibaragi, and G.-F. Hu, "Epithelial-mesenchymal transition and cell cooperativity in metastasis", Cancer Research, vol. 69, no. 18, pp. 7135-7139, 2009.
24. C.-Y. Liu, J.-Y. Xu, X.-Y. Shi et al., "M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway", Laboratory Investigation, vol. 93, no. 7, pp. 844-854, 2013.
25. B. Toh, X. Wang, J. Keeble et al., "Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor", PLoS Biology, vol. 9, no. 9, article ID e1001162, 2011.
26. F. Iovino, S. Meraviglia, M. Spina et al., "Immunotherapy targeting colon cancer stem cells", Immunotherapy, vol. 3, no. 1, pp. 97-106, 2011.
27. C. P. Beier, P. Kumar, K. Meyer et al., "The cancer stem cell subtype determines immune infiltration of Glioblastoma", Stem Cells and Development, vol. 21, no. 15, pp. 2753-2761, 2012.
28. J. Yang, D. Liao, C. Chen et al., "Tumor-associated macrophages regulate murine breast cancer stem cells through a novel paracrine egfr/stat3/sox-2 signaling pathway", Stem Cells, vol. 31, no. 2, pp. 248-258, 2013.
29. K.-F. He, L. Zhang, C.-F. Huang et al., "CD163+ tumor-associated macrophages correlated with poor prognosis and cancer stem cells in oral squamous cell carcinoma", BioMed Research International, vol. 2014, article ID 838632, 9 pages, 2014.
30. T. X. Cui, I. Kryczek, L. Zhao et al., "Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CTBP2", Immunity, vol. 39, no. 3, pp. 611-621, 2013.
31. J. Bukur, S. Jasinski, and B. Seliger, "The role of classical and non-classical HLA class I antigens in human tumors", Seminars in Cancer Biology, vol. 22, no. 4, pp. 350-358, 2012.
32. Y.-L. Li, B.-G. Sun, T. Xiang, Z.-X. Chen, and S.-J. Zhang, "Effect of invigorating spleen and detoxification decoction on MHCI/MHCII in spleen-deficiency liver cancer rats survival", Journal of Chinese Medicinal Materials, vol. 37, no. 3, pp. 456-462, 2014.
33. Y.-C. Kuan, W.-T. Lee, C.-L. Hung, C. Yang, and F. Sheu, "Investigating the function of a novel protein from Anoectochilus formosanus which induced macrophage diferentiation through TLR4-mediated NF-κB activation", International Immunopharmacology, vol. 14, no. 1, pp. 114-120, 2012.
34. H. Zheng, B. Piao, H. Lin, L. Xiong, and B. Hua, "Influence of Feiliuping Extractum and its modified formulas on function of dendritic cells", Journal of Beijing University of Traditional Chinese Medicine, vol. 30, no. 8, pp. 525-528, 549, 577, 2007.
35. M. Villa-Morales and J. Fernández-Piqueras, "Targeting the Fas/FasL signaling pathway in cancer therapy", Expert Opinion on Therapeutic Targets, vol. 16, no. 1, pp. 85-101, 2012.
36. J. Li, G. Z. Sun, X. Qi, Y. X. Pei, H. F. Yan, and Y. H. He, "Effect of 'YangWeiKangLiu' granules on peripheral blood T-lymphocyte rDNA transcription activity and Fas expression in gastric cancer metastasis", Chinese Journal of Integrative Medicine, vol. 8, no. 4, pp. 253-255, 2002.
37. J. Li, G.-Z. Sun, H.-S. Lin et al., "The herb medicine formula 'Yang Wei Kang Liu' improves the survival of late stage gastric cancer patients and induces the apoptosis of human gastric cancer cell line through Fas/Fas ligand and Bax/Bcl-2 pathways", International Immunopharmacology, vol. 8, no. 9, pp. 1196-1206, 2008.
38. K. Li, Z. Dan, and Y.-Q. Nie, "Gastric cancer stem cells in gastric carcinogenesis, progression, prevention and treatment", World Journal of Gastroenterology, vol. 20, no. 18, pp. 5420-5426, 2014.
39. F. Mannello, "Understanding breast cancer stem cell heterogeneity: time to move on to a new research paradigm", BMC Medicine, vol. 11, article 169, 2013.
40. T. Szafarowski and M. J. Szczepanski, "Cancer stem cells in head and neck squamous cell carcinoma", Otolaryngologia Polska, vol. 68, no. 3, pp. 105-111, 2014.
41. J. Pasquier and A. Rafii, "Role of the microenvironment in ovarian cancer stem cell maintenance", BioMed Research International, vol. 2013, article ID 630782, 10 pages, 2013.
42. R. Xie, H. Long, and B. Zhu, "Cancer stem cell and tumor immunity", Immunological Journal, vol. 26, no. 10, pp. 909-912, 2010.
43. Y. Chang, Y. Zhao, H. Zhan, X. Wei, T. Liu, and B. Zheng, "Bufalin inhibits the differentiation and proliferation of human osteosarcoma cell line hMG63-derived cancer stem cells", Tumor Biology, vol. 35, no. 2, pp. 1075-1082, 2014.
44. T. Zhang, K. Wang, J. Zhang et al., "Huaier aqueous extract inhibits colorectal cancer stem cell growth partially via downregulation of the Wnt/β-catenin pathway", Oncology Letters, vol. 5, no. 4, pp. 1171-1176, 2013.
45. H. C. Pan, D. W. Lai, K. H. Lan et al., "Honokiol thwarts gastric tumor growth and peritoneal dissemination by inhibiting Tpl2 in an orthotopic model", Carcinogenesis, vol. 34, no. 11, pp. 2568-2579, 2013.
46. S. Ponnurangam, J. M. V. Mammen, S. Ramalingametal., "Honokiol in combination with radiation targets notch signaling to inhibit colon cancer stem cells", Molecular Cancer Therapeutics, vol. 11, no. 4, pp. 963-972, 2012.
47. M. I. Carvalho, I. Pires, J. Prada, and F. L. Queiroga, "A role for T-lymphocytes in human breast cancer and in canine mammary tumors", BioMed Research International, vol. 2014, article ID 130894, 11 pages, 2014.
48. T. F. Gajewski, H. Schreiber, and Y.-X. Fu, "Innate and adaptive immune cells in the tumor microenvironment", Nature Immunology, vol. 14, no. 10, pp. 1014-1022, 2013.
49. Y. Liu, "Antineoplastic synergistic party and lung YanNing party combined with chemotherapy treatment of advanced lung adenocarcinoma random parallel control study", Journal of Practical Traditional Chinese Internal Medicine, vol. 27, no. 6, pp. 111-113, 2013.
50. J. Guo, J.-Y. Wang, Z. Zheng, Q. Wang, and C.-S. Dong, "Effects of chinese herbal medicine Feiyanning Decoction on the ratio of CD4+ CD25+ regulatory T cells and expression of transcription factor Foxp3 in mice bearing lewis lung carcinoma", Journal of Chinese Integrative Medicine, vol. 10, no. 5, pp. 584-590, 2012.
51. C.-P. Wan, L.-X. Gao, L.-F. Hou et al., "Astragaloside II triggers T cell activation through regulation of CD45 protein tyrosine phosphatase activity", Acta Pharmacologica Sinica, vol. 34, no. 4, pp. 522-530, 2013.
52. D. Capece, M. Fischietti, D. Verzella et al., "The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages", BioMed Research International, vol. 2013, article ID 187204, 15 pages, 2013.
53. Q.-J. Guo and J. Li, "The role of tumor-associated macrophages in remodeling tumor immune microenvironment", Tumor, vol. 33, no. 10, pp. 922-927, 2013.
54. G. Chen, K.-K. Li, C.-H. Fung et al., "Er-Miao-San, a traditional herbal formula containing Rhizoma Atractylodis and Cortex Phellodendri inhibits inflammatory mediators in LPS-stimulated RAW264.7 macrophages through inhibition of NF-kB pathway and MAPKs activation", Journal of Ethnopharmacology, vol. 154, no. 3, pp. 711-718, 2014.
55. T. Zhao, Y. Feng, J. Li et al., "Schisandra polysaccharide evokes immunomodulatory activity through TLR 4-mediated activation of macrophages", International Journal of Biological Macromolecules, vol. 65, pp. 33-40, 2014.
56. L.-Z. Meng, B.-Q. Lin, B. Wang et al., "Mycelia extracts of fungal strains isolated from Cordyceps sinensis differently enhance the function of RAW 264.7 macrophages", Journal of Ethnopharmacology, vol. 148, no. 3, pp. 818-825, 2013.
57. S. Zhang, S. Nie, D. Huang, J. Huang, Y. Wang, and M. Xie, "Polysaccharide from Ganoderma atrum evokes antitumor activity via Toll-like receptor 4-mediated NF-kB and mitogenactivated protein kinase signaling pathways", Journal of Agricultural and Food Chemistry, vol. 61, no. 15, pp. 3676-3682, 2013.
58. J. Wang, X. Tong, P. Li, H. Cao, and W. Su, "Immuno-enhancement effects of Shenqi Fuzheng Injection on cyclophosphamide-induced immunosuppression in Balb/c mice", Journal of Ethnopharmacology, vol. 139, no. 3, pp. 788-795, 2012.
59. B. Seliger and C. Massa, "The dark side of dendritic cells: development and exploitation of tolerogenic activity that favor tumor outgrowth and immune escape", Frontiers in Immunology, vol. 4, article 419, 2013.
60. Y. Ma, G. V. Shurin, D. W. Gutkin, and M. R. Shurin, "Tumor associated regulatory dendritic cells", Seminars in Cancer Biology, vol. 22, no. 4, pp. 298-306, 2012.
61. Y.-H. Zhang and Y.-H. Liu, "Influence of TCM therapy for supplementing Pi and nourishing Shen on dendritic cell function in patients with chronic hepatitis B treated by lamivudine", Chinese Journal of Integrative Medicine, vol. 15, no. 1, pp. 60-62, 2009.
62. H.-G. Zheng, B.-K. Piao, and B.-J. Hua, "Effect of feiliuping ointment and its disassembled prescriptions on dendritic cell of mice with transplanted Lewis lung cancer", Zhongguo Zhong Xi Yi Jie He Za Zhi, vol. 30, no. 12, pp. 1288-1291, 2010.
63. Y. M. Zhou, B. K. Piao, H. G. Zheng et al., "Influence on DC stimulating LPAK anti-tumor activity by feiliuping extract and its decomposed recipe", Cancer Research on Prevention and Treatment, vol. 40, no. 1, pp. 3-6, 2013.
64. Y. S. Khaled, B. J. Ammori, and E. Elkord, "Myeloid-derived suppressor cells in cancer: recent progress and prospects", Immunology and Cell Biology, vol. 91, no. 8, pp. 493-502, 2013.
65. J. Li, X. Chen, H. S. Lin, J. J. Oppenheim, and O. M. Z. Howard, "Inhibitory effect of Sheng Qi Formula (SQF) on Gr-1+ CD11b+ myeloid immunosuppressor cells (MIC) in the 4T1 murine mammary cancer model", AACR Annual Meeting Abstract, vol. 2008, article 5336, 9th AACR Annual Meeting, San Diego, Calif, USA, April 2008, 2008.
66. M. Taniguchi, K. I. Seino, and T. Nakayama, "The NKT cell system: bridging innate and acquired immunity", Nature Immunology, vol. 4, no. 12, pp. 1164-1165, 2003.
67. H. Wei, R. Sun, W. Xiao et al., "Traditional Chinese medicine Astragalus reverses predominance of Th2 cytokines and their up-stream transcript factors in lung cancer patients", Oncology Reports, vol. 10, no. 5, pp. 1507-1512, 2003.
68. H. Wei, R. Sun, W. Xiao et al., "Type two cytokines predominance of human lung cancer and its reverse by traditional Chinese medicine TTMP", Cellular & Molecular Immunology., vol. 1, no. 1, pp. 63-70, 2004.
69. X. Z. Chen, Z. Y. Cao, L. M. Liao, Z. Z. Liu, and J. Du, "Application of serum pharmacology in evaluating the antitumor effect of Fuzheng Yiliu Decoction from Chinese medicine", Chinese Journal of Integrative Medicine, vol. 20, no. 6, pp. 450-455, 2014.
70. Q. Wang and D. Y. Chen, "Effect of Aidi injection on peripheral blood expression of Th1/Th2 transcription factors and cytokines in patients with esophageal squamous cell carcinoma during radiotherapy", Zhongguo Zhong Xi Yi Jie He ZaZhi, vol. 29, no. 5, pp. 394-397, 2009.
71. Z. Xu, X. Chen, Z. Zhong, L. Chen, and Y. Wang, "Ganoderma lucidum polysaccharides: immunomodulation and potential anti-tumor activities", The American Journal of Chinese Medicine, vol. 39, no. 1, pp. 15-27, 2011.
72. F. N. Razali, A. Ismail, N. Z. Abidin, and A. S. Shuib, "Stimulatory effects of polysaccharide fraction from Solanum nigrum on RAW 264.7 murine macrophage cells", PLoS ONE, vol. 9, no. 10, article ID e108988, 2014.
73. S. H. Bae, J. B. Park, Y. F. Zheng et al., "Pharmacokinetics and tissue distribution of ginsenoside Rh2 and Rg3 epimers afer oral administration of BST204, a purifed ginseng dry extract, in rats", Xenobiotica, vol. 44, no. 12, pp. 1099-1107, 2014.
74. Z. Y. Tan, W. N. Xiong, X. Z. Huang, and J. Q. Liang, "Pharmacokinetics and bioavailability of ginsenoside Rg1 in rats", Zhong Yao Cai, vol. 36, no. 7, pp. 1121-1123, 2013.
75. D. Peng, H. Wang, C. Qu, L. Xie, S. M. Wicks, and J. Xie, "Ginsenoside Re: its chemistry, metabolism and pharmacokinetics", Chinese Medicine, vol. 7, article 2, 2012.
76. Y. Ming, Z. Chen, L. Chen et al., "Ginsenoside compound K attenuates metastatic growth of hepatocellular carcinoma, which is associated with the translocation of nuclear factorkB p65 and reduction of matrix metalloproteinase-2/9", Planta Medica, vol. 77, no. 5, pp. 428-433, 2011.
77. A. G. Musende, A. Eberding, W. Jia, E. Ramsay, M. B. Bally, and E. T. Guns, "Rh2 or its aglycone aPPD in combination with docetaxel for treatment of prostate cancer", Prostate, vol. 70, no. 13, pp. 1437-1447, 2010.
78. W. Huihui, C. Yulong, and M. Junhua, "Molecular mechanism of immunity regulated by TCM in tumor patients", China Journal of Chinese Medicine, vol. 29, no. 197, pp. 1405-1408, 2014.
79. B. Wang and M. Z. Chen, "Astragaloside IV possesses antiarthritic effect by preventing interleukin 1β-induced joint infammation and cartilage damage", Archives of Pharmacal Research, vol. 37, no. 6, pp. 793-802, 2014.
80. S. Sun, K. Zheng, H. Zhao et al., "Regulatory efect of astragalus polysaccharides on intestinal intraepithelial γδT cells of tumor bearing mice", Molecules, vol. 19, no. 9, pp. 15224-15236, 2014.
81. M. R. Stockler, F. Hilpert, M. Friedlander et al., "Patientreported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer", Journal of Clinical Oncology, vol. 32, no. 13, pp. 1309-1316, 2014.
82. S. Malempati, B. Weigel, A. M. Ingle et al., "Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group", Journal of Clinical Oncology, vol. 30, no. 3, pp. 256-262, 2012.
83. T. J. Molina, D. Canioni, C. Copie-Bergman et al., "Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensifed chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/Lymphoma Study Association phase III trial LNH 03-2B", Journal of Clinical Oncology, vol. 32, no. 35, pp. 3996-4003, 2014.
84. A. Ribas, R. Keford, M. A. Marshall et al., "Phase III randomized clinical trial comparing tremelimumab with standardof-care chemotherapy in patients with advanced melanoma", Journal of Clinical Oncology, vol. 31, no. 5, pp. 616-622, 2013.
85. S. L. Topalian, M. Sznol, D. F. McDermott et al., "Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab", Journal of Clinical Oncology, vol. 32, no. 10, pp. 1020-1030, 2014.
86. J. Vansteenkiste, M. Zielinski, A. Linder et al., "Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results", Journal of Clinical Oncology, vol. 31, no. 19, pp. 2396-2403, 2013.
87. J. R. Brahmer, "Harnessing the immune system for the treatment of non-small-cell lung cancer", Journal of Clinical Oncology, vol. 31, no. 8, pp. 1021-1028, 2013.
88. X. Yu, H. Zhao, L. Liu et al., "A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocelluar carcinoma", Journal of Clinical Immunology, vol. 34, no. 2, pp. 194-203, 2014.
89. M. J. Atherton and B. D. Lichty, "Evolution of oncolytic viruses: novel strategies for cancer treatment", Immunotherapy, vol. 5, no. 11, pp. 1191-1206, 2013.
90. M. Daher, M. E. Lacouture, D. Rathkopf et al., "Case series of dermatologic events associated with the insulin-like growth factor receptor 1 inhibitor cixutumumab", Journal of Clinical Oncology, vol. 29, no. 21, pp. e638-e640, 2011.
91. M. Liu, H. Tan, X. Zhang et al., "Hematopoietic effects and mechanisms of Fufang E'jiao Jiang on radiotherapy and chemotherapy-induced myelosuppressed mice", Journal of Ethnopharmacology, vol. 152, no. 3, pp. 575-584, 2014.
92. C. Zhao, J. Chen, B. Yu et al., "Effect of modified Taohongsiwu decoction on patients with chemotherapy-induced hand-foot syndrome", Journal of Traditional Chinese Medicine, vol. 34, no. 1, pp. 10-14, 2014.
93. B. C. He, J. L. Gao, B. Q. Zhang et al., "Tetrandrine inhibits Wn t/β-catenin signaling and suppresses tumor growth of human colorectal cancer", Molecular Pharmacology, vol. 79, no. 2, pp. 211-219, 2011.
94. W. C. S. Cho and K. N. Leung, "In vitro and in vivo anti-tumor efects of Astragalus membranaceus", Cancer Letters, vol. 252, no. 1, pp. 43-54, 2007.
95. Z. Chen, L. Y. Chen, P. Wang, H. Y. Dai, S. Gao, and K. Wang, "Tumor microenvironment varies under different TCM ZHENG models and correlates with treatment response to herbal medicine", Evidence-Based Complementary and Alternative Medicine, vol. 2012, article ID 635702, 10 pages, 2012.